An Israeli healthcare provider said Wednesday that the Pfizer Inc COVID-19 vaccine was 95% effective in a trial of 602,000 people, confirming the drug dealer’s effectiveness results.
Maccabi Health Care Services, which covers more than a quarter of all Israelis, said in a statement that only 608 people tested positive for COVID-19 more than a week after taking the second of two doses of Pfizer necessary to obtain.
The comparison was against a group of 528,000 Israelis with a similar background who did not receive the vaccine, Maccabi said. Of those, 20,621 tested positive.
“By comparing the proportion of new cases between the vaccine groups and still with vaccines, the effectiveness of the vaccine in Israel is currently estimated at 95%, seven days or more after the vaccine. get a second dose, “Maccabi said.
Most of the 608 infectious vaccines reported only mild symptoms, such as a headache or cough, Maccabi said. Some 21 needed hospitalization, and seven had severe symptoms, he said.
The data by Maccabi confirm efficacy results by Pfizer and its German partner BioNTech, which also found after a late-stage trial that their vaccine was 95% effective.
Nearly 44% of 9.1 million Israeli citizens have received at least one picture of the Pfizer vaccine, making the country the world’s largest study of effectiveness.
On Wednesday, Clalit, Israel ‘s largest healthcare provider, reported a 94% drop in COVID-19 symptomatic cases among 600,000 people who had received both doses of Pfizer.